Neovacs SA (FR:ALNEV) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neovacs SA, a French biotech firm, announced changes in its share capital and total number of voting rights, following a consolidation and the issuance of new shares. The company, known for its innovative kinoid® technology for treating autoimmune diseases, also informed about the potential market risks due to dilutive financing operations. Investors are cautioned about the possible impact on share value and capital dilution from these financial strategies.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.